Lexaria Bioscience FCF Growth
The Year-over-Year Free Cash Flow Growth of Lexaria Bioscience (LEXX) as of Oct 13, 2026 is -109.42 %. In the previous year, Year-over-Year Free Cash Flow Growth was 17.33 % — a change of -731.24% (lower).
Get this data via API
Financial Data API
FCF Growth
-109.42 %
YoY
-731.24%
Last updated:
The Lexaria Bioscience FCF Growth history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Growth | YoY |
|---|---|---|
| -109.42 % | -731.24% | |
| 17.33 % | -176.12% | |
| -22.77 % | +7.83% | |
| -21.12 % | -60.46% | |
| -53.41 % | -279.65% | |
| 29.73 % | -166.08% | |
| -44.99 % | -33.20% | |
| -67.35 % | -47.56% | |
| -128.44 % | -330.50% | |
| 55.72 % | -107.23% | |
| -770.49 % | — |
Lexaria Bioscience Stock analysis
Frequently Asked Questions about Lexaria Bioscience stock
Year-over-Year Free Cash Flow Growth of Lexaria Bioscience is -109.42 % in 2025.
On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.
FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.
To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.
Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Lexaria Bioscience historically and in real time.
Growth — Lexaria Bioscience
All Key Metrics — Lexaria Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth